William Raines - Aug 23, 2024 Form 4 Insider Report for cbdMD, Inc. (YCBD)

Role: Director
Signature: /s/ William Raines III
Stock symbol: YCBD
Transactions as of: Aug 23, 2024
Transactions value $: $0
Form type: 4
Date filed: 8/30/2024, 04:02 PM
Previous filing: Apr 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	YCBD	Common Stock	Award	$0	+75K	+810.29%	$0.00	84.3K	Aug 23, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Settlement, Purchase and Release Agreement dated August 23, 2024, entered into between the Issuer, CBD Industries, LLC and Majik Medicine, LLC ("Majik"), the Reporting Person was appointed as the true and lawful attorney, agent and proxy, with full power of substitution, for Majik for the issuance of 75,000 shares for 12 months from the Transaction Date (the "Proxy Period"). During the Proxy Period, the Reporting Person is entitled to (i) vote the shares at all shareholder meetings of the Issuer, (ii) execute instruments, consents, directions or other documents relative to the corporate affairs of the Issuer, (iii) calling for the approval or disapproval of any corporate act or transaction by the shareholders of the Issuer, and (iv) vote or otherwise act, upon any and all matters and questions relating to the Issuer. The Reporting Person shall vote in accordance with the recommendation of a majority of the independent members of the Issuer's Board of Directors.

Content

Pursuant to the Settlement, Purchase and Release Agreement dated August 23, 2024, entered into between the Issuer, CBD Industries, LLC and Majik Medicine, LLC ("Majik"), the Reporting Person was appointed as the true and lawful attorney, agent and proxy, with full power of substitution, for Majik for the issuance of 75,000 shares for 12 months from the Transaction Date (the "Proxy Period"). During the Proxy Period, the Reporting Person is entitled to (i) vote the shares at all shareholder meetings of the Issuer, (ii) execute instruments, consents, directions or other documents relative to the corporate affairs of the Issuer, (iii) calling for the approval or disapproval of any corporate act or transaction by the shareholders of the Issuer, and (iv) vote or otherwise act, upon any and all matters and questions relating to the Issuer. The Reporting Person shall vote in accordance with the recommendation of a majority of the independent members of the Issuer's Board of Directors.